Study of the efficacy and safety of sequential use of the drugs Mexidol and Mexidol FORTE 250 in the treatment of stroke

Karpov S.M.; Morozova M.Yu.; Muravyov K.A.; Vyshlova I.A.; Kantemirova F.S.

doi:https://doi.org/10.17116/jnevro202212203259

Karpov S.M.

Stavropol State Medical University

Morozova M.Yu.

City Clinical Hospital No. 3

Muravyov K.A.

City Clinical Hospital No. 3

Vyshlova I.A.

Stavropol State Medical University

Kantemirova F.S.

Georgievsky Medical Academy

Study of the efficacy and safety of sequential use of the drugs Mexidol and Mexidol FORTE 250 in the treatment of stroke

Authors:

Karpov S.M., Morozova M.Yu., Muravyov K.A., Vyshlova I.A., Kantemirova F.S.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(3‑2): 59‑62

DOI: 10.17116/jnevro202212203259

Read: 2513 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Karpov SM, Morozova MYu, Muravyov KA, Vyshlova IA, Kantemirova FS. Study of the efficacy and safety of sequential use of the drugs Mexidol and Mexidol FORTE 250 in the treatment of stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(3‑2):59‑62. (In Russ.)
https://doi.org/10.17116/jnevro202212203259

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To evaluate the effect of Mexidol on the recovery of cognitive functions in patients after ischemic stroke (IS).

MATERIAL AND METHODS

We examined 70 patients with acute IS, who were randomized into 2 groups by random sampling; The 1st group consisted of patients who, against the background of the main standard therapy for 14 days, received Mexidol intravenously, 500 mg 1 time per day, followed by oral administration of Mexidol FORTE 250, 750 mg per day for 60 days (40 patients; 28 men, 12 women). Group 2 consisted of 30 patients (21 men, 9 women) who received only standard therapy.

RESULTS

Baseline scores on the MoCA and MMSE scales did not differ between the two groups. Retesting showed that the improvement on these scales was statistically more significant in the 1st group. The analysis of indicators of the evoked potential P300 confirmed a more pronounced positive trend in the 1st group (p<0.01).

CONCLUSION

The use of sequential therapy with Mexidol is accompanied by a more complete recovery of cognitive functions in patients who have undergone IS.

Keywords:

stroke

acute cerebrovascular accident

cognitive impairment

Mexidol

Mexidol FORTE 250

Authors:

Karpov S.M.

Stavropol State Medical University

Morozova M.Yu.

City Clinical Hospital No. 3

Muravyov K.A.

City Clinical Hospital No. 3

Vyshlova I.A.

Stavropol State Medical University

Kantemirova F.S.

Georgievsky Medical Academy

Received:

11.01.2022

Accepted:

19.01.2022

Close metadata

References:

Mozaffarian D, Benjamin EJ, Go AS, at al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016;133(4):38-360. https://doi.org/10.1161/CIR.0000000000000350
Insul’t. Rukovodstvo dlja vrachej. Pod red. Stahovskoj LV, Kotova SV. 2-e izd., dop. i pererab. M.: OOO «Medicinskoe informacionnoe agentstvo»; 2018. (In Russ.).
Levin OS. Diagnostika i lechenie demencii v klinicheskoi praktike. M.: MEDpress-inform; 2014. (In Russ.).
Stulin ID, Musin RS, Surikova IL, et al. Rol’ instrumental’nogo monitoringa v diagnostike i prognozirovanii ONMK. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2003;103:9:154-160. (In Russ.).
Isajkin AI, Chernyshova EA, Jahno NN. Primenenie nejroprotektivnoj terapii pri insul’tah i cherepno-mozgovoj travme. Trudnyj Pacient. 2012;10:11:18-21. (In Russ.).
Prokopenko SV, Mozhejko EJu, Shvecova IN. Vosstanovlenie kognitivnyh funkcij posle insul’ta s ispol’zovaniem stimuljacii sensornyh zon mozga. Doktor.Ru. 2017;11(140):13-18. (In Russ.).
Red’ko AN, Zav’jalova VV, Hohlova IV, Karipidi RK. Sovremennye problemy organizacii i ocenka kachestva okazanija medicinskoj pomoshhi bol’nym s ostrymi narushenijami mozgovogo krovoobrashhenija v uslovijah pervichnogo sosudistogo otdelenija. Medicinskij Vestnik Severnogo Kavkaza. 2015;10:3:259-262. (In Russ.). https://doi.org/10.14300/mnnc.2015.10060
Malygin AJu, Hohlov AL, Mel’nikova JuE. Kompleksnaja harakteristika jeffektivnosti statinov pri ishemicheskom insul’te. Medicinskij Vestnik Severnogo Kavkaza. 2017;12:1:28-31. (In Russ.). https://doi.org/10.14300/mnnc.2017.12008
Efimova MJu, Ivanova NE, Alekseeva TM, et al. Molekuljarnye biomarkery kognitivnyh narushenij pri ishemicheskom insul’te. Medicinskij Vestnik Severnogo Kavkaza. 2019;14(3):567-571. (In Russ.). https://doi.org/10.14300/mnnc.2019.14121
Kispaeva TT, Ivanova GE, Volchenkova OV, Samsygina OM. Printsipy i metody kognitivnoi reabilitatsii bol’nykh v ostrom periode tserebral’nogo insul’ta. Lechebnaya Fizkul’tura i Sportivnaya Meditsina. 2009;7(67):48-57. (In Russ.).
Voronina TA. Geroprotektivnye jeffekty jetilmetilgidroksipiridina sukcinata v jeksperimental’nom issledovanii. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2020;120(4):81-87. (In Russ.). https://doi.org/10.17116/jnevro202012004181
Koval’chuk VV, Skoromec AA. Vozmozhnosti meksidola pri vosstanovlenii pacientov posle insul’ta. Medlajn-jekspress. 2009;4-5(203):4-6. (In Russ.).
Stakhovskaya L.V., Shamalov N.A., Khasanova D.R., et al. Results of a randomized double blind multicenter placebo-controlled, in parallel groups trial of the efficacy and safety of prolonged sequential therapy with mexidol in the acute and early recovery stages of hemispheric ischemic stroke (EPICA). Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2017;3(2):34-39. (In Russ.). https://doi.org/10.17116/jnevro20171173255-65